close

Agreements

Date: 2012-09-17

Type of information: R&D agreement

Compound: biomarkers to predict Alzheimer\'s disease

Company: GE Healthare (USA) VTT Technical Research Centre of Finland (Finland)

Therapeutic area: Neurodegenerative diseases

Type agreement:

R&D

Action mechanism:

Disease: Alzheimer's disease

Details:

VTT and GE Healthcare are developing novel biomarkers to predict Alzheimer\'s disease (AD). In 2010 GE Healthcare entered into \"biosignatures initiative\" alliance with Janssen Pharmaceutica to develop diagnostic biosignatures for pre-symptomatic identification of AD. As part of this programme, VTT will apply serum metabolite profiling to validate their recently discovered biochemical signature, as well as to discover novel biomarker candidates predictive of progression to AD.
VTT\'s research professor Matej Oreši? said: \"We are excited about the prospect of collaborating with GE Healthcare to accelerate its research programs and to further develop our biomarker towards a clinical assay applicable in healthcare setting. VTT has over the past years built unique metabolomics and systems biology platforms and acquired vast amount of knowledge on metabolic profiles and pathways in human health and disease, which allow us to identify disease-specific biochemical signatures and pathways. We believe that integration of metabolomics into the GE\'s and Janssen\'s biosignatures initiative will lead to better tools for early detection of AD and may also lead to better therapeutic options.\"

Financial terms:

Latest news:

Is general: Yes